Novartis arthritis drug fails to prove it is significantly better than rival

A clinical trial of Novartis’s Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday. Novartis said Cosentyx, when used to treat active psoriatic arthritis, “narrowly missed statistical significance for superiority” versus Humira, a drug made by AbbVie. “While Cosentyx narrowly missed statistical significance for superiority…. it showed numerically higher results versus Humira,” Novartis said following the results of a head-to-head trial. …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.